THRD
Signal
Mixed11
Price
1
Move-0.09%Quiet session
Volume
1
Volume5.4× avgSurge — unusual activity
Technical
1
RSIRSI 45Momentum negative
PRICE
Prev Close
5.39
Open
5.38
Day Range
52W Range3.18 – 16.02
3.18
16.02
17% of range
VOLUME & SIZE
Avg Volume
262.8K
FUNDAMENTALS
P/E Ratio
-4.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Performance
1D
5D
1M
3M
-1.82%
6M
+53.71%
YTD
-51.27%
1Y
-60.15%
Best: 6M (+53.71%)Worst: 1Y (-60.15%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
revenue -94% YoY
Valuation
FAIR
P/E not available
Health
MODERATE
CR 54.1 · FCF negative
Neutral
Key MetricsTTM
Market Cap$242.79M
Revenue TTM$48.0K
Net Income TTM-$53.45M
Free Cash Flow-$41.70M
Gross Margin22.9%
Net Margin-60293.8%
Operating Margin-73239.6%
Return on Equity-10.4%
Return on Assets-10.3%
Debt / Equity0.01
Current Ratio54.10
EPS TTM$-0.64

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
50/100
Liquidity
54.10Strong
Leverage
0.01Strong
Coverage
0.0xConcern
ROE
-10.4%Concern
ROIC
-12.8%Concern
Cash
$285MStrong
ANALYST COVERAGE5 analysts
HOLD
+253.2%upside to target
L $3.60
Med $19.00consensus
H $23.00
Buy
120%
Hold
480%
1 Buy (20%)4 Hold (80%)0 Sell (0%)
Full report →
Stock Health
Composite Score
1 of 5 signals bullish
3/10
Technicals
RSI RangeRSI 45 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 54.10 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 20, 2026
In 95 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

PullbackGolden Cross · 50D leads 200D by 26.0%

-0.1% vs SMA 50 · +25.9% vs SMA 200

Momentum

RSI45.1
Neutral territory
MACD-0.00
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$16.02+197.8%
EMA 50
$5.38+0.1%
Current
$5.38
EMA 200
$4.29-20.3%
52W Low
$3.18-40.9%
52-Week RangeNear 52-week low
$3.1817th %ile$16.02
Squeeze SetupVolume-based
Distribution Pressure

Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.

20-Day Money Flow
Acc days:2
Dist days:2
Edge:Even
Volume Context
Avg Vol (50D)265K
Recent Vol (5D)
478K+80%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 2 analysts
Analyst revisions:EPS↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2024
$0-$1.15
±12%
Low2
FY2025
$0-$0.88
±11%
Low2
FY2026(current)
$0-$0.97
±1%
Low2
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryTHRD
Last 8Q
+26.6%avg beat
Beat 5 of 8 quartersMissed 3 Estimates rising
+51%
Q4'23
+152%
Q1'24
+39%
Q2'24
+10%
Q3'24
-6%
Q4'24
+19%
Q1'25
-35%
Q2'25
-18%
Q3'25
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Morgan StanleyEqual-Weight → Overweight
Aug 8
UPGRADE
Morgan StanleyEqual-Weight
Dec 16
DOWNGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Conner Edward R.Chief Medical …
$32K
Nov 8
SELL
Bvf Partners L P/ilOther: See Exp…
$7.7M
Oct 29
SELL
Bvf Partners L P/ilOther: See Exp…
$5.7M
Oct 29
SELL
Bvf Partners L P/ilOther: See Exp…
$924K
Oct 29
SELL
Conner Edward R.Chief Medical …
$40K
Oct 28
SELL
Conner Edward R.Chief Medical …
$72K
Sep 19
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
BARCLAYS PLC
0
2
Point72 (DIFC) Ltd
0
3
TAKEDA PHARMACEUTICAL CO LTD
0
4
Cubist Systematic Strategies, LLC
0
5
Nuveen Asset Management, LLC
37K
6
Boxer Capital, LLC
2.0M
7
BlackRock Inc.
1.4M
News & Activity

THRD News

About

third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. our lead product candidate, thb001, is the first highly selective, oral small-molecule kit inhibitor to enter clinical development. with promising drug-like properties and an encouraging early clinical profile, thb001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
THRD
$5.38+0.00%$243M1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.96%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-2.64%50.3+398824.8%-4085.6%1500